Last reviewed · How we verify
ISTp-DP
ISTp-DP is a drug that targets the immune system to treat various conditions.
ISTp-DP is a drug that targets the immune system to treat various conditions. Used for Prevention of organ rejection in transplant patients.
At a glance
| Generic name | ISTp-DP |
|---|---|
| Also known as | Eurartesim, Duocotexin |
| Sponsor | Kenya Medical Research Institute |
| Drug class | Immunosuppressant |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
ISTp-DP works by modulating the immune response to prevent rejection in organ transplant patients. It is a form of immunosuppressive therapy that helps to reduce the risk of graft rejection and improve patient outcomes.
Approved indications
- Prevention of organ rejection in transplant patients
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Headache
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ISTp-DP CI brief — competitive landscape report
- ISTp-DP updates RSS · CI watch RSS
- Kenya Medical Research Institute portfolio CI